Transaction DateRecipientSharesTypePriceValue
12th February 2021Fredric N Eshelman2,875,000Grant/award etc.$7.29$20,958,750.00
1st February 2021Anthony Y Sun13,077Open or private sale$37.23$486,885.48
1st February 2021Anthony Y Sun12,417Open or private sale$37.68$467,844.00
1st February 2021Anthony Y Sun1,300Open or private sale$38.54$50,107.98
15th January 2021Ernest Mario41,216Exercise of in-the-money or at-the-money derivatives securities (usually options)$2.27$93,560.32
2nd December 2020Anthony Y Sun6,283Open or private sale$52.70$331,122.90
2nd December 2020Anthony Y Sun7,878Open or private sale$51.67$407,021.60
2nd December 2020Anthony Y Sun3,411Open or private sale$49.79$169,838.12
2nd December 2020Anthony Y Sun9,222Open or private sale$50.90$469,361.07
24th November 2020Anthony Y Sun100Open or private sale$47.56$4,756.00
Eyenovia logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Edenovia, Inc. engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine.

Ticker: EYEN
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1682639
Employees: 24
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags